Clinical Trial Update: Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating prophylactic octreotide to prevent or reduce diarrhea in patients receiving lapatinib with capecitabine for metastatic brea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Lapatinib (Lapatinib)
• OCTREOTIDE (OCTREOTIDE ACETATE)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cancer | Phase 2 | Status: TERMINATED | Results posted: 2019-07-15